uncategorized

Partex.AI and leadXpro announce collaboration to expand indications and support out-licensing of A2BR antagonist program

Eschborn, Germany and Villigen, Switzerland — 27/01/2026 — Partex.AI (“Partex”), an AI-driven therapeutic asset incubator and accelerator, and leadXpro AG (“leadXpro”), a Switzerland-based pharmaceutical research and development company, today announced that they have entered into a collaboration agreement focused on expanding the therapeutic potential and supporting the future out-licensing of leadXpro’s adenosine A2B receptor (A2BR) […]

New collaboration between leadXpro and Orbion!

Membrane proteins serve as a cell’s vital link to its external environment and play crucial roles in both health and disease. Although they make up only about a quarter of the human proteome, they are the targets of more than half of all approved drugs. However, studying these proteins in the lab is challenging due […]

leadXpro and Alipheron are combining their cutting-edge technologies to bring a new level of innovation to early drug discovery.

By applying intelligent algorithms to detect new drugs in trillions of molecules By using high-tech Cryo-EM to elucidate structures of membrane bound proteins By accelerating structure-based lead discovery to address unmet medical needs

Cumulus Oncology and leadXpro Achieve Critical Milestone in GPR68 Drug Discovery Project

Edinburgh, Scotland, and Villigen, Switzerland, 13 August 2024 – Cumulus Oncology, Europe’s first oncology-focused biotech creation company, announces that, in partnership with its collaborator leadXpro (LXP), key milestones have been achieved in their protein structure driven GPR68 drug discovery project. As a result, Cumulus has licensed the small molecule compounds and associated IP created during […]

Golgi Neurosciences and leadXpro announce collaboration on GPR65 modulators

Milan, Italy, and Villigen, Switzerland 29th May 2024. Today, we are happy to announce our partnership with Golgi Neurosciences, a pioneering company-creator boutique dedicated to developing therapies for neurodegenerative diseases.Together, we created significant progress with different classes of positive and negative modulators of GPR65, a proton-sensing G protein–coupled receptor (GPCR). This receptor is involved in […]